Business
ImmunoForge to Host Strategic Partnering Meetings During J.P. Morgan Healthcare Conference 2026
ImmunoForge Co., Ltd. (Co-CEOs Sung-Min Ahn and Kiho Chang), a clinical-stage biopharmaceutical company specializing in rare diseases, today announced that its leadership team will be in San Francisco during the 43rd Annual J.P. Morgan Healthcare Conference (January 12–15, 2026) to conduct strategic 1-on-1 meetings with global pharmaceutical companies and investors.
About this update from Nh Investment & Securities Co.ltd.
[{"type":"list","items":[{"val":[{"type":"text","content":"Focusing on global out-licensing of Phase 2 assets PF1801 and PF1804.","length":69,"tagName":"p"}]},{"val":[{"type":"text","content":"Company to engage with global big pharma in San Francisco to accelerate U.S. clinical entry.","length":92,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":161,"olType":false},{"type":"text","content":"SEOUL, South Korea, Jan. 1, 2026 /PRNewswire/ -- ImmunoForge Co., Ltd. (Co-CEOs Sung-Min Ahn and Kiho Chang), a clinical-stage biopharmaceutical company specializing in rare diseases, today announced that its leadership team will be in San Francisco during the 43rd Annual J.P. Morgan Healthcare Conference (January 12–15, 2026) to conduct strategic 1-on-1 meetings with global pharmaceutical companies and investors.","length":417,"tagName":"p"},{"type":"image","alt":"ImmunoForge's key highlights for partnering during J.P. Morgan Healthcare Conference 2026","displaySize":"","headline":null,"caption":"ImmunoForge's key highlights for partnering during J.P. Morgan Healthcare Conference 2026","className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":206,"url":"https://media.zenfs.com/en/prnewswire.com/87cc30234153cc081f0cec9ddaaf1407"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/vDex.OXj_YrPsMzyf1KDcQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTM2MztjZj13ZWJw/https://media.zenfs.com/en/prnewswire.com/87cc30234153cc081f0cec9ddaaf1407","width":400,"height":206}},"href":"https://mma.prnewswire.com/media/2852243/ImmunoForge_s_key_highlights_partnering_J_P_Morgan_Healthcare_Conference_2026.html","hrefExternal":true,"rel":"nofollow"},{"type":"text","content":"Instead of a formal stage presentation, ImmunoForge is focusing on high-level private partnering sessions to discuss the clinical progression and licensing of its key pipelines. The company's primary objective is to secure strategic partners capable of spearheading U.S. clinical trials for its Phase 2 assets.","length":314,"tagName":"p"},{"type":"text","content":"Key Highlights for Partnering:","length":30,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Monthly long-acting ELP (Elastin-Like Polypeptide) platform: Peptide conjugation and Protein fusion possible","length":113,"tagName":"p"}]},{"val":[{"type":"text","content":"BBB penetrating ELP (...